| Literature DB >> 35640325 |
E Delgado-Parada1, M Alonso-Sánchez2, J L Ayuso-Mateos3, M Robles-Camacho4, A Izquierdo3.
Abstract
INTRODUCTION: the COVID-19 pandemic had an impact on hospital admissions. The clinical profiles of patients referred to liaison psychiatry teams (LPT) remained stable over the last few decades. We postulate changes in patient profiles due to the COVID-19 pandemic.Entities:
Keywords: Consultation liaison psychiatry; Coronavirus; Delirium; Impact; Psychiatry
Mesh:
Year: 2022 PMID: 35640325 PMCID: PMC9124364 DOI: 10.1016/j.psychres.2022.114651
Source DB: PubMed Journal: Psychiatry Res ISSN: 0165-1781 Impact factor: 11.225
Clinical and sociodemographic characteristics of the sample.
| Variable | Total sample (n = 384) | PRE-COVID (n = 163) | COVID (n = 221) | U/χ2 ( |
|---|---|---|---|---|
| Age (years), median (iqr) | 66.0 (27.0) | 62.0 (79.0) | 67.0 (62.0) | 2.006 (.045)* |
| Sex, n (%) | .052 (.819) | |||
| 184 (47.9) | 77 (47.2) | 107 (48.4) | ||
| 200 (52.1) | 86 (52.8) | 114 (51.6) | ||
| Total time of hospitalization (days), median (iqr) | 23.0 (21.0) | 14.0 (252.0) | 12.0 (165.0) | -.601 (.548) |
| Time of attention by the LPT (days), median (iqr) | 4.0 (8.0) | 4.0 (64.0) | 4.0 (98.0) | 1.296 (.195) |
| Hospital unit, n (%) | 7.131 (.028)* | |||
| 266 (69.3) | 102 (62.6) | 164 (74.2) | 5.962 (.015)* | |
| 66 (17.2) | 37 (22.7) | 29 (13.1) | 6.045 (.014)* | |
| 52 (13.5) | 24 (14.7) | 28 (12.7) | .338 (.651) | |
| Psychiatric reasons for consultation, n (%) | 12.018 (.100) | |||
| 119 (31.0) | 44 (27.0) | 75 (33.9) | 2.114 (.146) | |
| 80 (20.8) | 36 (22.1) | 44 (19.9) | .269 (.604) | |
| 114 (29.7) | 43 (26.4) | 71 (32.1) | 1.484 (.223) | |
| 24 (6.3) | 14 (8.6) | 10 (4.5) | 2.644 (.104) | |
| 25 (6.5) | 17 (10.4) | 8 (3.6) | 7.147 (.008)* | |
| 9 (2.3) | 4 (2.5) | 5 (2.3) | .015 (.902) | |
| 10 (2.6) | 4 (2.5) | 6 (2.7) | .025 (.874) | |
| 3 (0.8) | 1 (0.6) | 2 (0.9) | .103 (.748) | |
| Reason for admission, n (%) | 97.252 (<.001)* | |||
| 68 (17.7) | 37 (22.7) | 31 (14.0) | 4.841 (.028)* | |
| 20 (5.2) | 15 (9.2) | 5 (2.3) | 9.152 (.002)* | |
| 31 (8.1) | 14 (8.6) | 17 (7.7) | .102 (.750) | |
| 68 (17.7) | 26 (16.0) | 42 (19.0) | .600 (.438) | |
| 55 (14.3) | 32 (19.6) | 23 (10.4) | 6.505 (.011)* | |
| 85 (22.1) | N/A | 85 (38.5) | 80.515 (<.001)* | |
| 57 (14.8) | 39 (23.9) | 18 (8.1) | 18.484 (<.001)* | |
| Substance use, n (%) | 9.235 (.161) | |||
| 310 (80.7) | 121 (74.2) | 189 (85.5) | 7.682 (.006)* | |
| 48 (12.5) | 28 (17.2) | 20 (9.0) | 5.666 (.017)* | |
| 3 (0.8) | 2 (1.2) | 1 (0.5) | .726 (.394) | |
| 11 (2.9) | 6 (3.7) | 5 (2.3) | .678 (.410) | |
| 2 (0.5) | 1 (0.6) | 1 (0.5) | .047 (.828) | |
| 1 (0.3) | - | 1 (0.5) | .739 (.390) | |
| 9 (2.3) | 5 (3.1) | 4 (1.8) | .648 (.421) | |
| Number of substances, n (%) | 19.152 (.002)* | |||
| 310 (80.7) | 121 (74.2) | 189 (85.5) | ||
| 54 (14.1) | 35 (21.5) | 19 (8.6) | ||
| 5 (1.3) | - | 5 (2.3) | ||
| 11 (2.9) | 4 (2.5) | 7 (3.2) | ||
| 2 (0.5) | 1 (0.6) | 1 (0.5) | ||
| 2 (0.5) | 2 (1.2) | - | ||
| Diagnosis given by LPT, n (%) | 16.462 (<.001)* | |||
| 85 (22.1) | 52 (31.9) | 33 (14.9) | 15.674 (<.001)* | |
| 250 (65.1) | 90 (55.2) | 160 (72.4) | 12.192 (<.001)* | |
| 49 (12.8) | 21 (12.9) | 28 (12.7) | .004 (.951) | |
| Diagnosis given by LPT coded by DSM-V, n (%) | 36.028(<.001)* | |||
| 27 (7.0) | 10 (6.1) | 17 (7.7) | .348 (.555) | |
| 23 (6.0) | 16 (9.8) | 7 (3.2) | 7.364 (.007)* | |
| 35 (9.1) | 22 (13.5) | 13 (5.9) | 6.566 (.010)* | |
| 2 (0.5) | 2 (1.2) | - | 2.726 (.099) | |
| 109 (28.4) | 34 (20.9) | 75 (33.9) | 7.893 (.005)* | |
| 40 (10.4) | 22 (13.5) | 18 (8.1) | 2.880 (.090) | |
| 83 (21.6) | 23 (14.1) | 60 (27.1) | 9.413 (.002)* | |
| 20 (5.2) | 13 (8.0) | 7 (3.2) | 4.393 (.036)* | |
| 30 (7.8) | 14 (8.6) | 16 (7.2) | .237 (.626) | |
| 15 (3.9) | 7 (4.3) | 8 (23.6) | .114 (.736) | |
| Number of diagnosis DSM-V, n (%) | 9.930 (.007)* | |||
| 249 (64.8) | 119 (73.0) | 130 (58.8) | ||
| 111 (28.9) | 39 (23.9) | 72 (32.6) | ||
| 24 (6.3) | 5 (3.1) | 19 (8.6) | ||
| Referral, n (%) | 9.886 (.042)* | |||
| 145 (38.1) | 58 (36.0) | 87 (39.5) | .489 (.484) | |
| 148 (38.8) | 66 (41.0) | 82 (37.3) | .542 (.462) | |
| 21 (5.5) | 12 (7.5) | 9 (4.1) | 2.018 (.155) | |
| 37 (9.7) | 19 (11.8) | 18 (8.2) | 1.389 (.239) | |
| 30 (7.9) | 6 (3.7) | 24 (10.9) | 6.611 (.010)* | |
| Prescription, n (%) | 1.146 (.284) | |||
| 268 (69.8) | 109 (66.9) | 159 (71.9) | ||
| 116 (30.2) | 54 (33.1) | 62 (8.1) | ||
| Deprescription, n (%) | 2.088 (.148) | |||
| 179 (46.6) | 69 (42.3) | 110 (49.8) | ||
| 205 (53.4) | 94 (57.7) | 111 (50.2) | ||
| Number of previous treatments, n (%) | 3.004 (.223) | |||
| 107 (27.9) | 40 (24.5) | 67 (30.3) | ||
| 142 (37.0) | 68 (41.7) | 74 (33.5) | ||
| 135 (35.2) | 55 (33.7) | 80 (36.2) | ||
| Number of treatments at discharge, n (%) | .361 (.835) | |||
| 42 (11.0) | 17 (10.4) | 25 (11.4) | ||
| 200 (52.2) | 88 (54.0) | 112 (50.9) | ||
| 141 (36.8) | 58 (35.6) | 83 (37.7) | ||
| Barthel index before admission, median (iqr) | 100.0 (5.0) | 100.0 (95.0) | 100 (80.0) | 2.237 (.025)* |
| Barthel index during admission, median (iqr) | 60.0 (44.0) | 60.0 (100.0) | 60.0 (100.0) | -1.191 (.234) |
| Loss of quantitative functionality, median (iqr) | 25.0 (35.0) | 20.0 (100.0) | 35.0 (100.0) | 2.209 (.027)* |
| Lawton index before admission, median (iqr) | 8.0 (2.0) | 8.0 (8.0) | 8.00 (8.0) | -1.954 (.051) |
Abbreviations: IQR: Interquartile range; LPT: Liaison Psychiatry Teams; ICU: Intensive Care Unit.
Prescription profile in both periods, before and after the LPT evaluation.
| COMPLETE SAMPLE | PERIOD 1 (PRECOVID) | PERIOD 2 (COVID) | |||
|---|---|---|---|---|---|
| Pre- Evaluation by LPT | Post-Evaluation by LPT | Pre- Evaluation by LPT | Post-Evaluation by LPT | Pre- Evaluation by LPT | Post-Evaluation by LPT |
| BZD(49%) | APS (45,2%) | BZD (52,8%) | APS (42,5%) | BZD (46,2%) | APS (46,8%) |
| APS (37,2%) | AD (42,3%) | APS (35,6%) | BZP (41,1%) | APS (38,5%) | AD (44,5%) |
| AD (24,7%) | BZP (31,5%) | AD (24,5%) | AD (39,3%) | AD (24,5%) | BZP (24,5%) |
| AED (10,2%) | AED (18,3) | AED (9,2%) | AED (12,9%) | AED (10,9%) | AED (22,3%) |
Abbreviations: LPT: liaison psychiatry team; BZD: benzodiazepines; APS: antipsychotics; AD: antidepressants; AED: antiepileptic drugs.
Inappropriate prescription in both periods, before and after the LPT evaluation.
| SAMPLE OVER AGES 65 YEARS (n= 205) | PERIOD 1 (PRECOVID) | McNemar test ( | PERIOD 2 (COVID) | McNemar test ( | ||||
|---|---|---|---|---|---|---|---|---|
| Pre-evaluation by LPT, n (%) | Post-evaluation by LPT, n (%) | Pre-evaluation by LPT, n (%) | Post-evaluation by LPT, n (%) | Pre-evaluation by LPT, n (%) | Post-evaluation by LPT, n (%) | |||
| IP | 93 (45.4) | 53 (25.9) | 39 (48.8) | 29 (36.3) | 2.893 (.089) | 54 (43.2) | 24 (19.2) | 21.025 (<.001)* |
| STOPP | 87 (42.4) | 35 (17.1) | 35 (43.8) | 17 (21.3) | 11.115 (.001)* | 52 (41.6) | 18 (14.4) | 25.929 (<.001)* |
| START | 10 (4.9) | 18 (8.8) | 6 (7.5) | 12 (15.0) | 4.167 (.031)* | 4 (3.2) | 6 (4.8) | .500 (.480) |
Abbreviations: LPT: liaison psychiatry team; IP: inappropriate prescription.